Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elena Baranova

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Arthritis Research & Therapy

2019

English

Related publications

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

2017

English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

SKIN The Journal of Cutaneous Medicine

2017

English

Comparative Evaluation of the Long-Term Efficacy and Safety of the Infliximab Biosimilar BCD-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-Blind Phase Iii Clinical Study Asart-2

Nauchno-Prakticheskaya Revmatologiya

English

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Arthritis Research & Therapy

2019

English

Over-The-Counter Nicotine Patch Therapy for Smoking Cessation: Results From Randomized, Double-Blind, Placebo-Controlled, and Open Label Trials.

American Journal of Public Health

English

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

Journal of the American Academy of Dermatology

Dermatology

2016

English

BP-C1 in Treatment of Patients With Stage IV Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study and Additional Open-Label Treatment Phase.

Journal of Clinical Oncology

English

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

2018

English

Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 Months: Results From the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Elena Baranova

FKB327, an Adalimumab Biosimilar, Versus the Reference Product: Results of a Randomized, Phase III, Double-Blind Study, and Its Open-Label Extension

Related publications

OP0021 Efficacy and Safety Results of a Phase Iii Study Comparing Fkb327, an Adalimumab Biosimilar, With the Adalimumab Reference Product in Patients With Active Rheumatoid Arthritis

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Comparative Evaluation of the Long-Term Efficacy and Safety of the Infliximab Biosimilar BCD-055 and Reference Infliximab in Patients With Ankylosing Spondylitis: Results of the International Multicenter Randomized Double-Blind Phase Iii Clinical Study Asart-2

Switch From Reference Etanercept to SDZ ETN, an Etanercept Biosimilar, Does Not Impact Efficacy, Safety, and Immunogenicity of Etanercept in Patients With Moderate-To-Severe Rheumatoid Arthritis: 48-Week Results From the Phase III, Randomized, Double-Blind EQUIRA Study

Over-The-Counter Nicotine Patch Therapy for Smoking Cessation: Results From Randomized, Double-Blind, Placebo-Controlled, and Open Label Trials.

Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Long-Term Efficacy and Safety Results From 2 Randomized Phase-Iii Studies and 1 Open-Label Long-Term Extension Study

BP-C1 in Treatment of Patients With Stage IV Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study and Additional Open-Label Treatment Phase.

AB0954 a Randomised, Double-Blind Trial Comparing the Efficacy, Safety and Immunogenicity of Msb11022, a Proposed Biosimilar of Adalimumab, Versus Adalimumab Originator in Patients With Moderate-To-Severe Plaque Psoriasis

Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 Months: Results From the Blinded Extension Phase of a Randomized, Double-Blind, Multicenter, Phase III Study